Profile data is unavailable for this security.
About the company
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
- Revenue in USD (TTM)37.17m
- Net income in USD-17.57m
- Incorporated2015
- Employees92.00
- LocationBiofrontera Inc120 Presidential Way,, Suite 330WOBURN 01801United StatesUSA
- Phone+1 (781) 245-1325
- Fax+1 (302) 655-5049
- Websitehttps://www.biofrontera-us.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LakeShore Biopharma Co Ltd | 89.02m | -14.47m | 5.33m | 573.00 | -- | 0.0371 | 0.801 | 0.0599 | -0.749 | -0.749 | 4.65 | 3.48 | 0.427 | 0.5001 | 1.30 | 155,360.70 | -6.94 | -- | -15.95 | -- | 82.47 | -- | -16.26 | -- | 0.7452 | -2.63 | 0.453 | -- | 7.24 | -- | 76.93 | -- | -- | -- |
| Sunshine Biopharma Inc | 37.32m | -5.99m | 5.74m | 52.00 | -- | 0.2204 | -- | 0.1538 | -2.03 | -2.03 | 10.74 | 5.31 | 1.21 | 2.09 | 10.12 | 717,764.30 | -19.47 | -68.65 | -23.80 | -89.02 | 33.01 | 32.79 | -16.06 | -81.12 | 2.09 | -209.95 | 0.00 | -- | 44.75 | 340.11 | -13.94 | -- | 370.33 | -- |
| cbdMD Inc | 19.19m | -4.38m | 7.36m | 42.00 | -- | 0.8655 | -- | 0.3835 | -3.92 | -3.92 | 4.77 | 0.8104 | 1.83 | 2.83 | 18.96 | -- | -19.44 | -48.27 | -44.42 | -54.99 | 62.37 | 63.95 | -10.63 | -85.60 | 1.20 | -- | 0.00 | -- | -1.50 | -14.45 | 43.21 | -- | -32.56 | -- |
| Tian'an Pharmaceutical Co Ltd | 10.65m | 3.14m | 8.00m | -- | 0.0445 | 0.0097 | 2.20 | 0.7511 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| Gelteq Ltd | 117.10k | -4.70m | 8.51m | 7.00 | -- | 0.7618 | -- | 72.68 | -0.4977 | -0.4977 | 0.0124 | 1.04 | 0.0078 | -- | 0.5155 | 16,728.25 | -31.47 | -17.38 | -40.60 | -19.16 | -- | -- | -4,011.74 | -4,507.46 | -- | -3.52 | 0.2106 | -- | -- | -- | -87.40 | -- | -- | -- |
| Biofrontera Inc | 37.17m | -17.57m | 9.07m | 92.00 | -- | -- | -- | 0.2441 | -1.84 | -1.84 | 4.07 | -0.2216 | 2.19 | 2.44 | 9.45 | 403,967.40 | -103.57 | -48.03 | -339.69 | -77.55 | 64.41 | 48.93 | -47.28 | -60.99 | 0.8033 | -47.48 | 2.37 | -- | 9.54 | 7.35 | 11.78 | -- | -35.51 | -- |
| Cuprina Holdings (Cayman) Ltd | 24.03k | -2.24m | 9.22m | 14.00 | -- | 1.52 | -- | 383.54 | -0.1234 | -0.1234 | 0.0013 | 0.2835 | 0.0049 | 13.39 | 0.7976 | 1,716.66 | -44.56 | -- | -131.50 | -- | -69.27 | -- | -9,194.46 | -- | 3.58 | -306.25 | 0.0244 | -- | -52.05 | -- | -39.39 | -- | -- | -- |
| Integrated Biopharma Inc | 53.43m | 672.00k | 9.31m | 153.00 | 14.14 | 0.4543 | 9.40 | 0.1742 | 0.0212 | 0.0212 | 1.71 | 0.6597 | 2.07 | 4.45 | 12.77 | 349,183.00 | 2.60 | 9.98 | 3.28 | 13.68 | 9.75 | 10.74 | 1.26 | 4.58 | 1.92 | -- | 0.0072 | -- | 8.02 | 0.5933 | 482.30 | -30.67 | -0.8556 | -- |
| CV Sciences Inc | 14.37m | -1.48m | 9.37m | 47.00 | -- | 6.09 | -- | 0.6525 | -0.008 | -0.008 | 0.078 | 0.0084 | 1.87 | 1.67 | 34.74 | 305,659.60 | -19.21 | -44.92 | -66.32 | -105.32 | 47.04 | 42.89 | -10.29 | -49.08 | 0.2125 | -2.02 | 0.3829 | -- | -1.87 | -21.80 | -177.18 | -- | -56.43 | -- |
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 9.52m | 233.00 | 0.0651 | 0.001 | 2.47 | 0.1345 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| Bon Natural Life Ltd | 18.67m | -1.99m | 10.12m | 96.00 | 18.63 | 0.2316 | -- | 0.5418 | 0.088 | 0.088 | 6.74 | 7.08 | 0.2541 | 6.07 | 1.64 | 194,486.40 | -2.79 | 5.82 | -3.97 | 7.86 | 20.77 | 28.53 | -10.98 | 10.83 | 1.61 | -4.44 | 0.1735 | 0.00 | -21.70 | 0.4899 | -577.58 | -- | 18.20 | -- |
| Nexgel Inc | 11.67m | -2.88m | 10.59m | 19.00 | -- | 2.04 | -- | 0.9075 | -0.3796 | -0.3796 | 1.53 | 0.6369 | 1.05 | 3.79 | 13.46 | 613,947.40 | -25.14 | -39.08 | -36.83 | -49.79 | 38.30 | 19.60 | -23.91 | -105.40 | 1.08 | -51.36 | 0.1439 | -- | 112.47 | 64.69 | -3.93 | -- | -- | -- |
| Akari Therapeutics PLC (ADR) | 0.00 | -15.77m | 10.67m | 8.00 | -- | -- | -- | -- | -0.600 | -0.600 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -65.57 | -112.46 | -136.47 | -257.78 | -- | -- | -- | -- | -- | -27.77 | 0.0854 | -- | -- | -- | -97.75 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Biofrontera Inc's reporting currency: US Dollar USD
20.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rosalind Advisors, Inc.as of 31 Dec 2025 | 1.14m | 9.79% |
| AIGH Capital Management LLCas of 31 Dec 2025 | 915.21k | 7.86% |
| Matejka & Partner Asset Management GmbHas of 29 Aug 2025 | 104.26k | 0.90% |
| Geode Capital Management LLCas of 31 Dec 2025 | 65.68k | 0.56% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 61.70k | 0.53% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 52.25k | 0.45% |
| Jane Street Capital LLCas of 31 Dec 2025 | 32.82k | 0.28% |
| Two Sigma Securities LLCas of 30 Sep 2025 | 20.79k | 0.18% |
| XTX Markets LLCas of 30 Sep 2025 | 18.00k | 0.16% |
| UBS Securities LLCas of 31 Dec 2025 | 10.37k | 0.09% |
More ▼
Data from 29 Aug 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
